Attached files

file filename
10-K - FORM 10-K - REGENERX BIOPHARMACEUTICALS INCd327746d10k.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - REGENERX BIOPHARMACEUTICALS INCd327746dex312.htm
EX-23.1 - CONSENT OF REZNICK GROUP, P.C - REGENERX BIOPHARMACEUTICALS INCd327746dex231.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - REGENERX BIOPHARMACEUTICALS INCd327746dex311.htm
EXCEL - IDEA: XBRL DOCUMENT - REGENERX BIOPHARMACEUTICALS INCFinancial_Report.xls

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of RegeneRx Biopharmaceuticals, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, J.J. Finkelstein, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in this report.

This certification accompanies this Report to which it relates, shall not be deemed “filed” with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

Date: April 4, 2012

 

/s/ J.J. Finkelstein

J.J. Finkelstein
President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)